A review of pharmacologic treatments for obsessive-compulsive disorder

Psychiatric Services

Volumn 54, Issue 8, 2003, Pages 1111-1118

  Kaplan, Alicia ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; DESIPRAMINE; FENFLURAMINE; FLUOXETINE; FLUTAMIDE; FLUVOXAMINE; HALOPERIDOL; IMMUNOGLOBULIN; INOSITOL; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORFLUOXETINE; OLANZAPINE; PAROXETINE; PEPTIDE HORMONE; PHENELZINE; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STEROID; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; VENLAFAXINE;

BEHAVIOR THERAPY; BIPOLAR DISORDER; BRAIN DEPTH STIMULATION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; MAJOR DEPRESSION; MANIA; NEUROSURGERY; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEROTONINERGIC SYSTEM; SIDE EFFECT; SYMPTOM; TRANSCRANIAL MAGNETIC STIMULATION; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHRONIC DISEASE; CLINICAL TRIALS; CLOMIPRAMINE; COMORBIDITY; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0042130101     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.54.8.1111     Document Type: Review

References (100)

1. Karno M, Golding JM: Obsessive compulsive disorder, in Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. Edited by Robins LN, Regier DA. New York, Free Press, 1991
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed rev. Washington, DC, American Psychiatric Association, 2000
3. Koran LM: Quality of life in obsessive-compulsive disorder. Psychiatric Clinics of North America 23:509-617, 2000
4. Koran LM, Thienemann ML, Davenport R: Quality of life for patients with obsessive-compulsive disorder. American Journal of Psychiatry 153:783-788, 1996
5. Hollander E, Stein D, Kwon JH, et al: Psychosocial function and economic costs of obsessive-compulsive disorder. CNS Spectrums 2:16, 1997
6. Calvocoressi L, Lewiss B, Harris M, et al: Family accommodation in obsessive-compulsive disorder. American Journal of Psychiatry 152:441, 1995
7. Leon AC, Portera L, Weissman MM: The social costs of anxiety disorders. British Journal of Pschiatry 27:19-22, 1995
8. Bystritsky A, Liberman RP, Hwang S, et al: Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders. Depression and Anxiety 14:214-218, 2001
9. Goodman WK, McDougle CJ, Barr LC, et al: Biological approaches to treatment-resistant OCD. Journal of Clinical Psychiatry 54:16-26, 1993
10. Rasmussen SA, Eisen JL, Pato MT: Current issues in the pharmacologic management of obsessive compulsive disorder. Journal of Clinical Psychiatry 54:4-9, 1993
11. Montgomery SA, Kasper S, Stein DJ, et al: Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. International Clinical Psychopharmacology 16:75-86, 2001
12. Mundo E, Bianchi L, Bellodi L: Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. Journal of Clinical Psychopharmacology 17:257-271, 1997
13. Grossman R, Hollander E: Treatment of obsessive-compulsive disorder with venlafaxine (letter). American Journal of Psychiatry 153:576-577, 1996
14. Ranch SL, O'Sullivan RL, Jenike MA: Open treatinent of obsessive-compulsive disorder with venlafaxine: a series of ten cases (letter). Journal of Clinical Psychopharmacoloy 16:81-83, 1996
15. Ravizza L, Albert U, Ceregato A: Venlafaxine in OCD. Presented at the International Obsessive-Compulsive Disorder Conference. Sardinia, Italy, Mar 29 to Apr 1, 2001
16. Thoren P, Asberg M, Cronholm B, et al: Clomipramine treatment in obsessive compulsive disorder: I. a controlled clinical trial. Archives of General Psychiatry 37:1281-1285, 1980
17. Flament MF, Rapoport JL, Berg CJ, et al: Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study. Archives of General Psychiatry 42:977-983, 1985
18. The Clomipramine Collaborative Study Group: Clomipramine in the treatment of patients with obsessive-compulsive disorder. Archives of General Psychiatry 48:730-738, 1991
19. DeVeaugh-Geiss J, Moroz G, Biederman J, et al: Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry 31:45-49, 1992
20. Liebowitz MR, Hollander E, Schneier F, et al: Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. Journal of Clinical Psychopharmacology 9:423-427, 1989
21. Tollefson GD, Rampey AH, Potvin JH, et al: A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry 51:559-567, 1994
22. Montgomery SA, McIntyre A, Osterheider M, et al: A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. European Neuropsychopharmacology 3:143-152, 1993
23. Perse TL, Greist JH, Jefferson JW, et al: Fluvoxamine treatment of obsessive-compulsive disorder. American Journal of Psychiatry 144:1543-1548, 1987
24. Goodman WK, Price LH, Rasmussen SA, et al: Efficacy of fluvoxamine in obsessive compulsive disorder. Archives of General Psychiatry 46:36-44, 1989
25. Jenike MA, Hymna S, Baer L, et al: A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. American Journal of Psychiatry 147:1209-1215, 1990
26. Greist JH: Fluvoxamine in OCD: A Multicenter Parallel Design Double-Blind Placebo-Controlled Trial. Presented at the 18th Collegium Internationale Neuro-Psychopharmacologicum Congress. Nice, France, June 28 to July 2, 1992
27. Hollander E, Koran LM, Goodman W, et al: A double-blind placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry 64:640-647, 2003
28. Jenike MA, Baer L, Summergrad P, et al: Sertraline in obsessive compulsive disorder: a double-blind comparison with placebo. American Journal of Psychiatry 147:923-928, 1990
29. Chouinard G, Goodman W, Greist JH, et al: Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacology Bulletin 26:279-284, 1990
30. Greist J, Chouinard G, Duboff E, et al: Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Archives of General Psychiatry 52:289-295, 1995
31. Greist JH, Jefferson JW, Kobak KA, et al: A one-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. International Clinics of Psychopharmacology 10:57-65, 1995
32. Koran LM, Hackett E, Rubin A, et al: Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. American Journal of Psychiatry. 159:88-95, 2002
33. Hollander E, Allen A, Steiner M, et al: Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Journal of Clinical Psychiatry, in press
34. McDougle CJ, Goodman WK, Leckman JF: Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without ties. Archives of General Psychiatry 51:302-308, 1994
35. McDougle CJ, Goodman WK, Price LJ, et al: Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry 147:652-654, 1990
36. Saxena S, Wang D, Bystritsky A, et al: Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry 57:303-306, 1996
37. Ravizza L, Barzega G, Bellino S, et al: Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacology Bulletin 32:677-682, 1996
38. McDougle CJ, Epperson CN, Pelton GH, et al: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Archives of General Psychiatry 57:794-801, 2000
39. Weiss EL, Potenza MN, McDougle CJ, et al: Olanzapine addition in obsessive-com-pulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. Journal of Clinical Psychiatry 60:524-527, 1999
40. Koran LM, Ringold AL, Elliot MA: Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 61:514-517, 2000
41. Bystritsky A, Ackerman DL, Rosen RM, et al: Augmentation of SSRI response in refractory OCD using adjunctive olanzapine: a placebo controlled trial. Presented at the International Obsessive-Compulsive Disorder Conference. Sardinia, Italy, Mar 29 to Apr 1, 2001
42. Markovitz PJ, Stagno SJ, Calabrese JR: Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. American Journal of Psychiatry 47:798-800, 1990
43. Jenike MA, Baer L, Buttolph L: Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry 52:13-14, 1991
44. Grady TA, Pigott TA, L'Heureux F, et al: Double-blind study of adjuvant buspirone for fluoxetine treated patients with obsessive-compulsive disorder. American Journal of Psychiatry 150:819-821, 1993
45. Pigott TA, L'Heureux F, Hill JL, et al: A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 12:11-18, 1992
46. McDougle CJ, Goodman WK, Leckman JF, et al: Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry 150:647-649, 1993
47. Hollander E, DeCaria CM, Schneier FR, et al: Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Journal of Clinical Psychiatry 51:119-123, 1990
48. De Montigny C: Enhancement of the 5-HT neurotransmission by antidepressant treatments. Journal of Physiology 77:455-461, 1981
49. Ruegg RG: Lithium plus fluoxetine treatment of obsessive compulsive disorder. Abstract presented at the annual meeting of the American Psychiatric Association, New York City, May 1990
50. Pigott TA, Pato MT, L'Heureux F, et al: A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive compulsive disorder. Journal of Clinical Psychopharmacology 11:242-248, 1991
51. McDougle CJ, Price LH, Goodman WK, et al: A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. Journal of Clinical Psychopharmacology 11:175-184, 1991
52. Leonard HL, Topol D, Bukstein O, et al: Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 33:792-794, 1994
53. Pigott TA, L'Heureux F, Rubenstein CF, et al: A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine. Abstract presented at the annual meeting of the American Psychiatric Association, Washington, DC, May 4, 1992
54. Marazziti D, Gemignani A, Dell'Osso L: Trazodone augmentation in OCD: a case series report. CNS Spectrums 4:48-49, 1999
55. Mattes JA: A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. International Clinical Psychopharmacology 1:170-173, 1986
56. Griest JH, Jefferson JW, Kobak KA, et al: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Archives of General Psychiatry 52:53-60, 1995
57. Piccinelli M, Pini S, Bellantouono C, et al: Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. British Journal of Psychiatry 166:424-443, 1995
58. Stein DJ, Spadaccni E, Hollander E: Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. International Clinical Psychopharmacology 10:11-18, 1995
59. Freeman CPL, Trimble MR, Deakrin JFW, et al: Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry 55:301-305, 1994
60. Koran LM, Cain JW, Dominguez RA, et al: Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. Journal of Clinical Psychopharmacology 16:121-129, 1996
61. Goodman WK, Ward H, Kablinger A, et al: Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. Journal of Clinical Psychiatry 58(suppl 5):32-49, 1997
62. Hollander E, Bienstock CA, Koran L, et al: Refractory obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical Psychiatry 63(suppl 6):20-29, 2002
63. Koran LM, Sallee FR, Pallanti S: Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry 54:396-401, 1997
64. Annesley PT: Nardil response in a chronic obsessive compulsive. British Journal of Psychiatry 115:748, 1969
65. Jenike MA, Baer L, Minichiello WE, et al: Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. American Journal of Psychiatry 154:1261-1264, 1997
66. Baxter LR Jr: Two cases of obsessive-compulsive disorder with depression responsive to trazodone. Journal of Nervous and Mental Disease 173:432-433, 1985
67. Piggott TA, L'Heureux F, Rubenstein CS, et al: A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 12:156-162, 1992
68. Jenike MA, Baer L: An open trial of buspirone in obsessive-compulsive disorder American Journal of Psychiatry 145:1285-1286, 1988
69. Hewlett WA: Novel pharmacological treatments of obsessive-compulsive disorder, in Obsessive-Compulsive Disorders. Edited by Hollander E, Stein DJ. New York, Marcel Dekker, 1997
70. Knesevich JW: Successful treatment of obsessive-compulsive disorder with clonidine hydrochloride. American Journal of Psychiatry 139:364-365, 1982
71. Hollander E, Fay M, Cohen B, et al: Serotonergic and noradrenergic sensitivity in obsessive compulsive disorder: behavioral findings. American Journal of Psychiatry 145:1015-1017, 1988
72. Hewlett WA, Vinogradov S, Agras WS: Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder Journal of Clinical Psychopharmacology 12:420-430, 1992
73. Hewlett WA, Vinogradov S, Agras WS: Clonazepam treatment of obsessions and compulsions. Journal of Clinical Psychiatry 51:158-161, 1990
74. Bodkin JA, White K: Clonazepam in the treatment of obsessive compulsive disorder associated with panic disorder in one patient. Journal of Clinical Psychiatry 40:265-266, 1989
75. Stein DJ, Hollander E, Mullen LS, et al: Comparison of clomipramine, alprazolam, and placebo in the treatment of obsessive-compulsive disorder. Human Psychopharmacology 7:389-395, 1992
76. Allen AJ, Leonard H, Swedo SE: Case study: a new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 34:307-311, 1995
77. Swedo SE, Rapoport JL, Cheslow DL, et al: High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. American Journal of Psychiatry 146:246-249, 1989
78. Perlmutter SJ, Leitman SF, Garvey MH, et al: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 354:1153-1158, 1999
79. Altemus M, Greenberg BD, Kenler D, et al: Open trial of flutamide for treatment of obsessive-compulsive disorder. Journal of Clinical Psychiatry 60:442-445, 1999
80. Fux M, Levine J, Aviv A, et al: Inositol treatment of obsessive-compulsive disorder. American Journal of Psychiatry 153:1219-1221, 1996
81. Karno M, Golding JM, Sorenson SB, et al: The epidemiology of obsessive compulsive disorder in five US communities. Archives of General Psychiatry 45:1094-1099, 1988
82. Rasmussen SA, Eisen JL: The epidemiology and differential diagnosis of obsessive compulsive disorder. Journal of Clinical Psychiatry 55:5-14, 1994
83. Eisen JL, Goodman WK, Keller MB, et al: Patterns of remission and relapse in obsessive-compulsive disorder: a two-year prospective study. Journal of Clinical Psychiatry 60:346-351, 1999
84. Cosoff S, Hafner RJ: The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder, and bipolar disorder. Ausindian and New Zealand Journal of Psychiatry 32:67-72, 1998
85. Kruger S, Cooke RG, Hasey GM, et al: Comorbidity of obsessive compulsive disorder m bipolar disorder. Journal of Affective Disorders 34:117-120, 1995
86. Fenton WS, McGiashan TH: The prognostic significance of obsessive-compulsive symptoms in schizophrenia. American Journal of Psychiatry 143:437-441, 1986
87. Eisen JL, Beer DA, Pato MT, et al: Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. American Journal of Psychiatry 154:271-273, 1997
88. Berman I, Kalinowski A, Berman SM, et al: Obsessive and compulsive symptoms in chronic schizophrenia. Comprehensive Psychiatry 365:6-10, 1995
89. Hwang MY, Morgan JE, Losconzcy MF: Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia. Journal of Neuropsychiatry and Clinical Neuroscience 12:91-94, 2000
90. Zohar J: Is there room for a new diagnostic subtype: the schizo-obsessive subtype? CNS Spectrums 2:49-50, 1997
91. Baker RW, Chengappa KNR, Baird JW, et al: Emergence of obsessive-compulsive symptoms during treatment with clozapine. Journal of Clinical Psychiatry 53:439-442, 1992
92. Patil VJ: Development of transient obsessive compulsive symptoms during treatment with clozapine (letter). American Journal of Psychiatry 149:272, 1992
93. Lykonras L, Zeruas IM, Gournellis R, et al: Olanzapine and obsessive-compulsive symptoms. European Neuropsychiatry 10:385-387, 2000
94. Kopala L, Honer WG: Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia (letter). American Journal of Psychiatry 151:1714-1715, 1994
95. Allen L, Tejera C: Treatment of clozapine induced OC symptoms with sertraline (letter). American Journal of Psychiatry 151:1096-1097, 1994
96. Poyurovsky M, Hermesh H, Weizman A: Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients. Journal of Clinical Neuropharmacology 19:305-313, 1996
97. Eisen JL, Beer D, Pato MT, et al: Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. Journal of Clinical Psychiatry 60:356-351, 1999
98. Rasmussen SA, Eisen JL: The epidemiology and clinical features of obsessive compulsive disorder, in Obsessive-Compulsive Disorders: Practical Management, 3rd ed. Edited by Jenike MA, Baer L, Minichiello WE. St Louis, Mosby, 1998
99. Baer L, Rauch SK, Ballantine T, et al: Cingulotomy for intractable obsessive-compulsive disorder. Archives of General Psychiatry 52:384-392, 1995
100. Greenberg BD, George MS, Martin DJ, et al: Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. American Journal of Psychiatry 154:867-869, 1997